• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chain Bridge I filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    11/13/24 7:39:02 AM ET
    $CBRG
    Blank Checks
    Finance
    Get the next $CBRG alert in real time by email
    false 0001845149 0001845149 2024-11-12 2024-11-12 0001845149 CBRGU:UnitseachconsistingofoneClassAordinaryshareandonehalfofoneredeemableWarranttoacquireoneClassAordinaryshareMember 2024-11-12 2024-11-12 0001845149 us-gaap:CommonClassAMember 2024-11-12 2024-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 12, 2024

     

    Chain Bridge I

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-41047   98-1578955

    (State or other jurisdiction of
    incorporation or organization)

      (Commission File Number)  

    (I.R.S. Employer
    Identification Number)

     

    8 The Green #17538
    Dover, DE

      19901
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (202) 656-4257

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one Class A ordinary share and one-half of one redeemable Warrant to acquire one Class A ordinary share   CBRGU   The Nasdaq Capital Market
    Class A ordinary shares, par value $0.0001 per share   CBRG   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 1.01.Entry Into A Material Definitive Agreement.

     

    As previously disclosed, on November 11, 2024, Chain Bridge I (the “Company”) entered into non-redemption agreements (the “Agreements”) and one or more investors (each, a “Backstop Investor”). On November 12, 2024, the Company and each Backstop Investor entered into Amendment No. to Non-Redemption Agreement (the “Amendment”) pursuant to which the parties agree to allow the Backstop Investors to purchase Acquired Shares (as defined in the Agreements) at any time prior to the extraordinary general meeting of the Company’s shareholders to be held at 11:00 a.m. Eastern Time on November 14, 2024 (the “Meeting”).

     

    The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the form of Amendment filed as Exhibit 10.1 hereto and incorporated herein by reference.

     

    Item 3.01.Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

     

    On November 12, 2024, the Company” received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (“Rule IM-5101-2”), the staff of Nasdaq (“Staff”) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting.

     

    Item 8.01.Other Events.

     

    As previously disclosed, the Company postponed its Meeting and, in connection with such postponement, the right of the public shareholders of the Company to redeem their Class A ordinary shares issued in the Company’s initial public offering (the “Public Shares”) for their pro rata portion of the funds available in the Company’s trust account was extended to November 12, 2024 (two business days before the postponed Meeting) (the “Redemption Deadline”).

     

    As of the Redemption Deadline, the pro rata portion of the trust account was approximately $11.49 per Public Share (the “Redemption Price”). The closing price of the Company’s Class A ordinary shares at the Redemption Deadline was $11.90. The Company cannot assure shareholders that they will be able to sell their Class A ordinary shares in the open market, even if the market price per share is higher than the Redemption Price stated above, as there may not be sufficient liquidity in its securities when such shareholders wish to sell their shares.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d)Exhibits.

     

    Exhibit
    Number
    Description
    10.1 Form Amendment No. 1 to Non-Redemption Agreement among Chain Bridge I and certain Backstop Investors signatory thereto
       
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: November 13, 2024

     

      CHAIN BRIDGE I
       
      By: /s/ Andrew Cohen
      Name: Andrew Cohen
      Title: Chief Executive Officer

     

     

     

    Get the next $CBRG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kucharchuk Andrew Albert

      3 - Chain Bridge I (0001845149) (Issuer)

      4/5/24 4:19:27 PM ET
      $CBRG
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Wiener Oliver

      3 - Chain Bridge I (0001845149) (Issuer)

      2/22/24 4:13:59 PM ET
      $CBRG
      Blank Checks
      Finance
    • New insider Cb Co-Investment Llc claimed ownership of 575,665 units of Class A Ordinary Shares (SEC Form 3)

      3 - Chain Bridge I (0001845149) (Issuer)

      2/20/24 7:34:04 PM ET
      $CBRG
      Blank Checks
      Finance

    $CBRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/14/24 1:46:48 PM ET
      $CBRG
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/14/24 12:49:36 PM ET
      $CBRG
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/13/24 4:37:52 PM ET
      $CBRG
      Blank Checks
      Finance

    $CBRG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CBRG
    SEC Filings

    See more
    • Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

      NEW YORK and SANTA BARBARA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The global cannabis pharmaceuticals market size was estimated at USD 3.4 billion in 2023 and is anticipated to grow at a CAGR of 53.3% from 2024 to 2030. The investor deck is now available on

      7/30/24 9:00:00 AM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

      Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP)The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal closeThe business combination is expected to be completed in the fourth quarter of 2024, with the combined company to be listed on Nasdaq Capital Markets under the ticker "PHYX" NEW YORK and SANTA BARBARA, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Phytani

      7/22/24 5:45:34 PM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I Will Redeem Public Shares

      Chain Bridge I (the "Company") (NASDAQ:CBRGU, CBRG, CBRGW))), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 (the "Public Shares"), effective as of the close of business on November 15, 2023, as the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the "Articles"). The Company concluded it would be unable to meet its expectations for quality and long-term return potential by completing an initial business combination by November 15, 2023 (twenty-four months from the closing of the Company

      10/31/23 4:00:00 PM ET
      $CBRG
      Blank Checks
      Finance
    • SEC Form 10-Q filed by Chain Bridge I

      10-Q - Chain Bridge I (0001845149) (Filer)

      11/19/24 5:29:41 PM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Chain Bridge I (0001845149) (Filer)

      11/19/24 6:05:29 AM ET
      $CBRG
      Blank Checks
      Finance
    • SEC Form NT 10-Q filed by Chain Bridge I

      NT 10-Q - Chain Bridge I (0001845149) (Filer)

      11/14/24 5:29:34 PM ET
      $CBRG
      Blank Checks
      Finance